Handelsbanken Fonder
NGM

Handelsbanken Fonder’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Handelsbanken Fonder’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$210K – 1767
2021
Q3 		$210K Buy
+10,000
New +$220K ﹤0.01% 1651

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Handelsbanken Fonder's NGM Position: Q4 2021 in Review

Handelsbanken Fonder sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2021, closing a stake of 10,000 shares — an estimated $210K sold.

Handelsbanken Fonder first reported a position in NGM in Q3 2021 and held it in 1 quarter. The position peaked at $210K in Q3 2021. 119 funds tracked by Wall St. Rank hold NGM as of Q4 2021.

  • Handelsbanken Fonder reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Handelsbanken Fonder sold 10,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $210K.
  • Handelsbanken Fonder first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • Handelsbanken Fonder's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $210K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Handelsbanken Fonder's 13F filing for Q4 2021, filed 8 Feb 2022.